wire - news in brief
Category
Results 101 - 150 of 382.
Prostate cancer research, important SNF grant goes to the IOR
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Universitŕ della Svizzera italiana), has received a 4-year grant
The Prostate cancer biology Group, led by Dr. Giuseppina Carbone at the Institute of Oncology Research (IOR, affiliated to USI Universitŕ della Svizzera italiana), has received a 4-year grant
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
Whether mobile phone or automatic toilets - electronic devices are becoming increasingly complex. And who hasn't heard stories of devices that fail precisely after the warranty has expired?
Self-driving cars, the automatic detection of cancer cells, online translation: deep learning makes it all possible. The ETH spin-off Mirage Technologies has developed a deep learning platform that aims to help start-ups and companies more quickly develop and optimise their products. The name has a fairytale feel to it, with its reference to mirages and the suggestion of illusion.
AveXis presents updated STRONG data at WMS demonstrating a higher mean increase in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores among older SMA Type 2 patients following one-time intrathecal administration of AVXS-101
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Taking sustainability into space
Things are changing in outer space: it is filling with debris, attracting private companies, and raising new technological challenges.
Things are changing in outer space: it is filling with debris, attracting private companies, and raising new technological challenges.
These days, Microsoft officially opens a lab in Zurich dedicated to researching mixed reality technologies and artificial intelligence.
Marc Angélil played a decisive role in shaping the teaching of architecture at ETH Zurich, both as professor and as temporary head of the department.
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
They are 16, determined and ready to dive into the exciting world of research: the first Ph.D students from the new USI Faculty of Biomedical Sciences presented themselves on Friday 20 September at t
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Novartis Kisqali delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea
Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So
Nine new professors appointed
Energy systems, cryptography and computer-aided simulation; interactions between people, animals and landscape, investigation of biosystems from the human brain to the nanometer scale: the incoming professors work in a wide range of cutting-edge research fields.
Energy systems, cryptography and computer-aided simulation; interactions between people, animals and landscape, investigation of biosystems from the human brain to the nanometer scale: the incoming professors work in a wide range of cutting-edge research fields.
A highlight at the FMI Annual Meeting 2019, which has taken place last week in the Swiss Alps (Grindelwald), was the Award Ceremony: the winners of the Ed Fischer Prize for best thesis, the Max Burge
SwissCube still going strong 10 years on
The tiny Swiss satellite, launched in September 2009, is still working. The fact that it has lasted so long is a testament to the skills of the students who built it.
The tiny Swiss satellite, launched in September 2009, is still working. The fact that it has lasted so long is a testament to the skills of the students who built it.
Vacuums are a vital part of the processes - such as freeze-drying - used to make and preserve countless everyday items and must be measured with precision. An EPFL spin-off, Hexisense, is bringing to market a gallium nitride-based chip that can measure the quantity of certain gas molecules cheaply and with unrivalled precision.
Four Swiss organisations, including UNIGE, receive funding from the European Union (EU) through OPENQKD, a secure quantum communication infrastructure.
History of technology: accolades to USI researcher Maria Rikitianskaia
The International Committee for the History of Technology (ICOHTEC) honoured Maria Rikitianskaia for her doctoral work which was unanimously voted as the best book on the history of technology, published in 2019 by young researchers. The researcher of USI Institute of Media and Journalism won the Turriano ICOHTEC Prize , dedicated to the best book on the history of technology written by a young researcher.
The International Committee for the History of Technology (ICOHTEC) honoured Maria Rikitianskaia for her doctoral work which was unanimously voted as the best book on the history of technology, published in 2019 by young researchers. The researcher of USI Institute of Media and Journalism won the Turriano ICOHTEC Prize , dedicated to the best book on the history of technology written by a young researcher.
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
Deepfakes - or fake videos produced to look real through the use of artificial intelligence - pose a growing challenge.
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti
The complexity of molecular structures in the cell is amazing. Having achieved great success in elucidating these structures in recent years, biologists are now taking on the next challenge: to find out more about how they are constructed. A joint research project between two groups from the University of Bern and ETH Zurich now provides insight into a very unusual construction process in the unicellular parasite Trypanosoma brucei.
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1
Solutions for the future of nutritional research
Every day, we choose the food we eat and influence our health, whether consciously or not. This link between diet and health is a core concern of nutritional scientists, who met in Bern from 7 to 12 September 2019 for the 16th annual conference of the NuGO nutrigenomics association.
Every day, we choose the food we eat and influence our health, whether consciously or not. This link between diet and health is a core concern of nutritional scientists, who met in Bern from 7 to 12 September 2019 for the 16th annual conference of the NuGO nutrigenomics association.
